GTG Stock Overview A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Genetic Technologies Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Genetic Technologies Historical stock prices Current Share Price AU$0.038 52 Week High AU$0.18 52 Week Low AU$0.038 Beta 0.46 1 Month Change 0% 3 Month Change n/a 1 Year Change -74.67% 3 Year Change -93.67% 5 Year Change -92.40% Change since IPO -98.42%
Recent News & Updates
Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index Dec 18
Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index Dec 17 Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million. Nov 27
Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023) Oct 04
Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform Aug 15 Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million. Aug 14
See more updates
Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index Dec 18
Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index Dec 17 Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million. Nov 27
Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023) Oct 04
Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform Aug 15 Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million. Aug 14
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million. Jul 27
Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO
Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide Jun 25
New major risk - Revenue and earnings growth Apr 25 Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million. Apr 24
New minor risk - Shareholder dilution Apr 22 Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million. Apr 20
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million. Apr 19
Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston Apr 12
Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare Mar 26
Independent Non-Executive Chairman recently bought AU$80k worth of stock Mar 08
New major risk - Financial position Feb 24 Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement Jan 06
New major risk - Market cap size Nov 24
Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023 Sep 30
Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia Sep 12
Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022) Sep 01
New minor risk - Financial data availability Aug 29
First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022) Feb 28 Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification Feb 10
Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer Feb 07
Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer Feb 04
Non-Independent Non-Executive Director recently sold AU$77k worth of stock Feb 03
Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes Dec 06
Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022 Oct 28 Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer
Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021) Aug 31
Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited. Jul 14 Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary
Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia Jul 01
Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model Jun 17
Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million May 17
Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release Feb 22
High number of new and inexperienced directors Dec 04
Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020) Sep 02
Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC. Aug 17
Company Secretary Justyn Stedwell has left the company Aug 05
Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC Jun 01
Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update Apr 27
Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test Mar 04
Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million. Jan 26 Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing Genetic Technologies Limited Announces Management Changes
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX Dec 04
Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020 Nov 06
Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020 Oct 28
Full year earnings released - AU$0.0015 loss per share Oct 27
Genetic Technologies Provides Update on COVID-19 Risk Test Oct 03
Full year earnings released - AU$0.0015 loss per share Sep 23
Full year earnings released - AU$0.0015 loss per share Sep 02
Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement Sep 02
Full year earnings released - AU$0.0015 loss per share Sep 01
Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million. Jul 22 Shareholder Returns GTG AU Life Sciences AU Market 7D 0% 1.1% -2.7% 1Y -74.7% 13.8% 6.5%
See full shareholder returns
Return vs Market: GTG underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility Is GTG's price volatile compared to industry and market? GTG volatility GTG Average Weekly Movement n/a Life Sciences Industry Average Movement 8.9% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: GTG's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine GTG's volatility change over the past year.
About the Company Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Show more Genetic Technologies Limited Fundamentals Summary How do Genetic Technologies's earnings and revenue compare to its market cap? GTG fundamental statistics Market cap AU$5.67m Earnings (TTM ) -AU$12.02m Revenue (TTM ) AU$9.67m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GTG income statement (TTM ) Revenue AU$9.67m Cost of Revenue AU$3.76m Gross Profit AU$5.91m Other Expenses AU$17.93m Earnings -AU$12.02m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.083 Gross Margin 61.12% Net Profit Margin -124.24% Debt/Equity Ratio 35.2%
How did GTG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 23:47 End of Day Share Price 2024/10/16 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Marc Kennis APP Securities Pty Ltd. Kevin DeGeeter Ladenburg Thalmann & Company Chris Kallos MST Financial Services Pty Limited
Show 0 more analysts 
